The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat their obstructive sleep apnea.

The United States Food and Drug Administration (FDA) has approved the weight-loss drug Tirzepatide — sold by the brand name Zepbound — for the treatment of Obstructive Sleep Apnoea (OSA), a condition in which the throat muscles sag and block air passages, resulting in difficulty breathing during sleep.

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.

Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for more than two years. But the drugmaker Eli Lilly is “currently meeting or exceeding demand” for all doses of these medicines and should continue to do so going forward, the FDA said in a December 19 statement.

FDA stated that Zepbound, part of the GLP-1 receptor agonist medicines that include Ozempic, was cleared to treat moderate to severe OSA in individuals with obesity. According to drugmaker Eli Lilly,

Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

ABC News' Dr. Darien Sutton breaks down the FDA’s approval of the popular weight loss medication for the treatment of obstructive sleep apnea in adults with obesity.